Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SKB103 for injection in HER2-negative breast cancer
CTR20263108Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB103 in breast cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Aug 2026; status: active.
02
Drugs
SKB103
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263108.